BridgeBio Pharma Inc’s recently made public that its Director Valantine Hannah unloaded Company’s shares for reported $0.17 million on Jun 10 ’25. In the deal valued at $40.00 per share,4,292 shares were sold. As a result of this transaction, Valantine Hannah now holds 1,764 shares worth roughly $74387.88.
Then, HANNAH A VALANTINE bought 4,292 shares, generating $171,680 in total proceeds.
Before that, Kumar Neil sold 75,000 shares. BridgeBio Pharma Inc shares valued at $2,504,978 were divested by the Chief Executive Officer at a price of $33.40 per share. As a result of the transaction, Kumar Neil now holds 4,798,447 shares, worth roughly $202.35 million.
Wolfe Research initiated its BridgeBio Pharma Inc [BBIO] rating to an Outperform in a research note published on June 17, 2025; the price target was $49. A number of analysts have revised their coverage, including Redburn Atlantic’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. Scotiabank began covering BBIO with “Sector outperform” recommendation on October 16, 2024. Oppenheimer started covering the stock on October 03, 2024. It rated BBIO as “a Perform”.
Price Performance Review of BBIO
On Monday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 1.07%% to $42.17. Over the last five days, the stock has gained 6.02%. BridgeBio Pharma Inc shares have risen nearly 52.75% since the year began. Nevertheless, the stocks have risen 53.70% over the past one year. While a 52-week high of $41.94 was reached on 06/23/25, a 52-week low of $21.62 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 41.58, which if violated will result in even more drops to 40.99. On the upside, there is a resistance level at 42.48. A further resistance level may holdings at 42.79.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-05-30, dropping by -0.19 million shares to a total of 21.99 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 22.18 million shares. There was a decline of -0.86%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 04, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $46 price target.
